Prostate cancer is focus of bioMérieux, ProteoSys deal
This article was originally published in Clinica
Executive Summary
French diagnostics company bioMérieux is set to combine with German biotechnology research firm ProteoSys to develop a urine-based confirmatory diagnostic for prostate cancer. The test will use the Annexin 3 biomarker, discovered by Mainz-based ProteoSys, and will be developed to run on bioMérieux’s Vidas analyser platform after an initial research phase. According to bioMérieux, when used alongside standard screening methods, the new test “could potentially reduce the number of biopsies conducted by up to 75%”. Financial details of the deal were not disclosed.